Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
Cancer Chemother Pharmacol
; 75(1): 17-23, 2015 Jan.
Article
in En
| MEDLINE
| ID: mdl-25322874
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Benzimidazoles
/
Camptothecin
/
Colorectal Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
MAP Kinase Kinase Kinases
/
Protein Kinase Inhibitors
/
Topoisomerase I Inhibitors
Type of study:
Clinical_trials
/
Etiology_studies
/
Incidence_studies
/
Observational_studies
Language:
En
Journal:
Cancer Chemother Pharmacol
Year:
2015
Type:
Article